Current trends in the clinical development of peptide therapeutics.
The development of peptides as drugs is attracting increasing attention from the pharmaceutical industry. This interest is at least partially a consequence of the widespread acceptance of therapeutic proteins by physicians and patients, and because of improvements to problems such as a short half-life and delivery issues. The markets for peptide-based compounds can be substantial, with six peptide drugs attaining global sales of more than US $750 million in 2008. To track trends in the clinical development and marketing approval of peptides, Tufts Center for the Study of Drug Development and Ferring Research Institute compiled publically available data for peptides that entered clinical trials sponsored by commercial firms, with a focus on peptide therapeutics, but also including peptide vaccines and diagnostics. The results provide an historical overview of the development of peptide therapeutics, and may inform strategic planning in this area.
Saladin
Pauline M
PM
Harvard University, Department of Health Policy and Management, School of Public Health,Kresge 4th floor, 677 Huntington Avenue, Boston, MA 02115, USA.
Zhang
Bodi D
BD
Reichert
Janice M
JM
D001291:Attitude of Health Personnel; D002986:Clinical Trials as Topic; D003132:Commerce / Q000639:trends; D017277:Drug Approval; D015195:Drug Design; D004345:Drug Industry / Q000191:economics / Q000639:trends*; D006801:Humans; D010342:Patient Acceptance of Health Care; D010455:Peptides / Q000191:economics / Q000627:therapeutic use*; D022223:Vaccines, Subunit / Q000276:immunology
D010455:Peptides; D022223:Vaccines, Subunit